A new chance to treat rheumatoid arthritis lung fibrosis?
- PMID: 36075241
- DOI: 10.1016/S2213-2600(22)00295-8
A new chance to treat rheumatoid arthritis lung fibrosis?
Conflict of interest statement
MS reports payments or honoraria for lectures and presentations from Bristol Myers Squibb, Pfizer, and Boehringer-Ingelheim and fees for participation on Advisory Board from Bristol Myers Squibb, Lilly, Amgen, Janssen, Boehringer-Ingelheim, and Celltrion. AM reports payments or honoraria for lectures and presentations from Bristol Myers Squibb, Lilly, and Boehringer-Ingelheim and reports fees for participation on Advisory Board from Bristol Myers Squibb, Lilly, and Boehringer-Ingelheim.
Comment on
-
Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.Lancet Respir Med. 2023 Jan;11(1):87-96. doi: 10.1016/S2213-2600(22)00260-0. Epub 2022 Sep 5. Lancet Respir Med. 2023. PMID: 36075242 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
